EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC 4.0

Impact of monthly headache days on migraine‐related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study

Richard B Lipton, Patricia Pozo-Rosich, Serena L Orr iD, Michael L Reed, Kristina M Fanning, Brett Dabruzzo, Dawn C Buse

Headache: The Journal of Head and Face Pain · 2023-11 · 63 (10) · 1448-1457

DOI: 10.1111/head.14629 ↗

Kurz gefasst

Kommentar in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 05.10.2023. Verfasst von Richard B Lipton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Quality of Life, Migraine Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Allergan (prior to its acquisition by AbbVie).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To characterize the direct impact of monthly headache days (MHDs) on health‐related quality of life (HRQoL) in people with migraine and the potential mediating effects of anxiety, depression, and allodynia.

Background

Although the general relationship between increased migraine frequency (i.e., MHDs) and reduced HRQoL is well established, the degree to which reduced HRQoL is due to a direct effect of increased MHDs or attributable to mediating factors remains uncertain.

Methods

Cross‐sectional baseline data from participants with migraine who completed the Core and Comorbidities/Endophenotypes modules in the 2012–2013 US Chronic Migraine Epidemiology and Outcomes (CaMEO) study, a longitudinal web‐based survey study, were analyzed. The potential contribution of depression, anxiety, and/or allodynia to the observed effects of MHDs on HRQoL as measured by the Migraine‐Specific Quality‐of‐Life Questionnaire version 2.1 (MSQ) was evaluated.

Results

A total of 12,715 respondents were included in the analyses. The MSQ domain scores demonstrated progressive declines with increasing MHD categories ( B = −1.23 to −0.60; p < 0.001). The observed HRQoL decrements associated with increasing MHDs were partially mediated by the presence of depression, anxiety, and allodynia. The MHD values predicted 24.0%–32.4% of the observed variation in the MSQ domains. Depression mediated 15.2%–24.3%, allodynia mediated 9.6%–16.1%, and anxiety mediated 2.3%–6.0% of the observed MHD effects on the MSQ.

Conclusions

Increased MHD values were associated with lower MSQ scores; the impact of MHDs on the MSQ domain scores was partially mediated by the presence of depression, anxiety, and allodynia. MHDs remain the predominant driver of the MSQ variation; moreover, most of the variation in the MSQ remains unexplained by the variables we analyzed. Future longitudinal analyses and studies may help clarify the contribution of MHDs, comorbidities, and other factors to changes in HRQoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeMigraine DisordersHumansCross-Sectional StudiesHyperalgesiaTreatment OutcomeHeadache

Stichwörter der Autor:innen

allodyniaanxietycomorbiditydepressionfunctional statushealth-related quality of life

Autor:innen und Institutionen

  • Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Headache Research Group, VHIR, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Vedanta Research, Chapel Hill, North Carolina, USA.

ORCID-Profile: Serena L Orr

Förderung

  • Allergan (prior to its acquisition by AbbVie)

Zitieren

APA

Lipton, R. B., Pozo-Rosich, P., Orr, S. L., Reed, M. L., Fanning, K. M., Dabruzzo, B., & Buse, D. C. (2023). Impact of monthly headache days on migraine‐related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache: The Journal of Head and Face Pain, 63(10), 1448-1457. https://doi.org/10.1111/head.14629

Vancouver

Lipton RB, Pozo-Rosich P, Orr SL, Reed ML, Fanning KM, Dabruzzo B, et al. Impact of monthly headache days on migraine‐related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache: The Journal of Head and Face Pain. 2023;63(10):1448-1457. doi:10.1111/head.14629

BibTeX
@article{Lipton2023,
  author = {Lipton, Richard B and Pozo-Rosich, Patricia and Orr, Serena L and Reed, Michael L and Fanning, Kristina M and Dabruzzo, Brett and Buse, Dawn C},
  title = {Impact of monthly headache days on migraine‐related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  volume = {63},
  number = {10},
  pages = {1448--1457},
  doi = {10.1111/head.14629}
}
Kostenlos starten →